Ready to ex­pand, Gen­Script rais­es $224M for CD­MO fo­cused on an­ti­bod­ies, cell and gene ther­a­pies

Chi­na’s Gen­Script has brought in new in­vestors to back its bi­o­log­ics-fo­cused sub­sidiary — to the tune of $224 mil­lion.

Gen­Script, which is list­ed in Hong Kong, dis­closed the Se­ries C for Gen­Script Pro­Bio in a fil­ing. The new funds will help “build up man­u­fac­tur­ing ca­pac­i­ty, fur­ther re­search and de­vel­op­ment ca­pa­bil­i­ties and op­por­tunis­ti­cal­ly ac­quire as­sets” to de­vel­op Pro­Bio’s con­tract de­vel­op­ment and man­u­fac­tur­ing busi­ness, the moth­er com­pa­ny wrote.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER